Next Article in Journal
Regulation of DNA Damage Response by Estrogen Receptor β-Mediated Inhibition of Breast Cancer Associated Gene 2
Next Article in Special Issue
Editorial of Special Issue “New Aspects of the Hepatocyte Growth Factor/c-Met System”
Previous Article in Journal / Special Issue
HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells
Article Menu

Export Article

Open AccessReview
Biomedicines 2015, 3(1), 149-181;

Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404, USA
Author to whom correspondence should be addressed.
Academic Editor: Giulia Ricci
Received: 22 January 2015 / Revised: 25 February 2015 / Accepted: 3 March 2015 / Published: 19 March 2015
(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
Full-Text   |   PDF [1248 KB, uploaded 19 March 2015]   |  


The hepatocyte growth factor (HGF): MET axis is a ligand-mediated receptor tyrosine kinase pathway that is involved in multiple cellular functions, including proliferation, survival, motility, and morphogenesis. Aberrancy in the HGF/MET pathway has been reported in multiple tumor types and is associated with tumor stage and prognosis. Thus, targeting the HGF/MET pathway has become a potential therapeutic strategy in oncology development in the last two decades. A number of novel therapeutic agents—either as therapeutic proteins or small molecules that target the HGF/MET pathway—have been tested in patients with different tumor types in clinical studies. In this review, recent progress in HGF/MET pathway-targeted therapy for cancer treatment, the therapeutic potential of HGF/MET-targeted agents, and challenges in the development of such agents will be discussed. View Full-Text
Keywords: HGF; MET; cancer treatment; new therapeutic agents; biomarker HGF; MET; cancer treatment; new therapeutic agents; biomarker

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zhang, Y.; Jain, R.K.; Zhu, M. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines 2015, 3, 149-181.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top